A Breakthrough in Lung Cancer Treatment
TAMC offers medical support for patients eligible for the new biological drug
New hope for lung cancer patients in Israel: an innovative biological treatment called Sevabertinib, currently in an advanced stage of clinical trials, is demonstrating exceptional effectiveness in treating tumors with HER2 mutations. At TAMC, a leading oncology center in Tel Aviv, we are already prepared to assist eligible patients.
Biological Therapy – Fewer Side Effects, More Hope
Sevabertinib is a targeted biological drug in tablet form. Recent clinical data shows that over 90% of patients responded to the treatment or were able to halt disease progression for several months. Unlike chemotherapy, this treatment targets only cancer cells, significantly reducing side effects.
TAMC – A Home for Advanced Oncology and Medical Innovation
At TAMC, we support lung cancer patients with personalized care in cooperation with genetic laboratories, leading experts, and research centers. We offer:
- Advanced genetic testing to identify HER2 and other mutations.
- Personalized medical guidance to assess eligibility for the new treatment.
- Second opinions from top lung cancer specialists.
Is It Already Available in Israel?
Sevabertinib is still in the research phase, but the available data is attracting global attention. The TAMC team closely follows developments and offers a consultation program for patients who wish to prepare for the drug’s approval in Israel or consider participation in international trials.
Who Might Benefit from This Treatment?
The treatment may be suitable for patients with progressive NSCLC (non-small cell lung cancer) carrying the HER2 mutation, who have not responded to previous therapies. A simple genetic test can determine eligibility.
TAMC – A private oncology center in Tel Aviv offering next-generation personalized medicine.
📅 Book an appointment today
Join the patients who have already chosen us for professional and personalized care.
📞 Phone: 073-3746844
📱 WhatsApp: 055-9231022
📧 Email: [email protected]